FDA Makes Revisions to Moderna’s COVID-19 Vaccine EUA to Increase Available Doses

News
Article

The first revision further clarifies the number of doses per vial for the vials that are already available, while the second revision allows for the availability of an additional multi-dose vial.

On April 1, 2021, FDA announced two revisions to the Moderna COVID-19 vaccine Emergency Use Authorization (EUA) to increase the number of vaccine doses available.

The first revision further clarifies the number of doses per vial for the vials that are already available, with the maximum number of 11 extractable doses, with a range of 10–11 doses, FDA said in a company press release. The second revision allows for the availability of an additional multi-dose vial which contains a maximum of 15 doses, with a range of 13–15 doses that can potentially be extracted.

Depending on the type of syringe and needle used to extract each dose, FDA warned that there may not be enough volume to extract more than 10 doses from the vial containing a maximum of 11 doses or more than 13 doses from the vial containing a maximum of 15 doses, according to the press release.

“Both of these revisions positively impact the supply of Moderna COVID-19 vaccine, which will help provide more vaccine doses to communities and allow shots to get into arms more quickly. Ultimately, more vaccines getting to the public in a timely manner should help bring an end to the pandemic more rapidly,” said Peter Marks, MD, PhD, director of FDA’s Center for Biologics Evaluation and Research, in the press release.

Source: FDA

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes